Sanj Patel Sells 48,565 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Key Points

• CEO Sanj Patel sold 48,565 shares on May 1 at an average $54.02 for $2.62M under a pre‑arranged Rule 10b5‑1 plan, reducing his ownership by about 50%, a move that may create short‑term negative sentiment despite being planned.
• Q1 beat and guidance raise: Kiniksa reported $0.27 EPS vs. $0.18 expected and $214.3M revenue (+55% YoY), management raised FY‑2026 revenue guidance, and product/pipeline catalysts (strong ARCALYST sales and a KPL‑387 readout due 2H‑2026) support upside.
• Market reaction and analyst support: the stock rose ~2.8% to $55.27 with above‑average volume, multiple brokers lifted price targets (examples: Jefferies, Canaccord, Citi), and institutional investors own roughly 54% of the shares.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CEO Sanj Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction on Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the transaction, the chief executive officer directly owned 48,565 shares of the company's stock, valued at $2,623,481.30. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 2.8%

Shares of KNSA traded up $1.49 during trading hours on Friday, hitting $55.27. 1,017,196 shares of the company were exchanged, compared to its average volume of 711,381. The company has a market cap of $4.23 billion, a price-to-earnings ratio of 61.41 and a beta of 0.06. The firm's fifty day moving average is $46.40 and its 200 day moving average is $43.12. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $24.85 and a fifty-two week high of $55.28.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.72%. The business had revenue of $214.27 million during the quarter, compared to analysts' expectations of $206.11 million. During the same quarter in the prior year, the business posted $0.11 earnings per share. Kiniksa Pharmaceuticals International's revenue was up 55.5% compared to the same quarter last year. Analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.17 EPS for the current year.

Key Stories Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and upgraded guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55% YoY); management raised FY‑2026 revenue guidance, improving near‑term revenue visibility. Q1 Results & Guidance
• Positive Sentiment: Analyst upgrades/target raises — multiple brokers lifted targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59), which supports buying interest and helped push the stock higher. Analyst Target Raises
• Positive Sentiment: Product and pipeline momentum — ARCALYST reported strong Q1 net product revenue and management raised expectations; KPL‑387 Phase‑2 readout (recurrent pericarditis) is expected 2H‑2026 with a planned Phase‑3 start by year‑end, offering future catalysts. Product & Pipeline
• Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted for investors who want to verify channel dynamics, margin assumptions and guidance drivers. Earnings Presentation
• Negative Sentiment: Large insider selling — CEO Sanj K. Patel executed significant sales (including 483,654 shares on Apr. 28 and additional tranches Apr. 29–30) under a pre‑arranged 10b5‑1 plan; director Barry Quart also sold ~13k shares. Heavy insider selling can create short‑term negative sentiment despite being pre‑planned. CEO SEC Filing
• Negative Sentiment: Director sale detail — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, reducing his stake materially; additional SEC filing here. Director SEC Filing

Analyst Ratings Changes

A number of research analysts recently issued reports on KNSA shares. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a research note on Friday, April 17th. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Wednesday. Canaccord Genuity Group lifted their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday. Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $60.86.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds have recently added to or reduced their stakes in KNSA. Rubric Capital Management LP grew its stake in shares of Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company's stock worth $155,320,000 after buying an additional 90,194 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company's stock valued at $128,409,000 after acquiring an additional 49,802 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Kiniksa Pharmaceuticals International by 45.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company's stock worth $41,481,000 after acquiring an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock worth $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC raised its position in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after purchasing an additional 67,452 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.